News

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...
ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...
In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...
In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...
Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.
An aflibercept biosimilar is “clinically equivalent” to the reference drug when used in the treatment of diabetic macular edema (DME), according to trial results published in JAMA Ophthalmology.
Aflibercept 2q8/pro re nata (PRN), or as-needed, group included 134 participants administered 2-mg intravitreal injections of aflibercept every 8 weeks after 5 initial monthly doses, ...
A non-inferiority comparison between aflibercept and bevacizumab as first-line treatment for macular edema associated with central retinal vein occlusion kicks off this summer, according to study ...
It agreed that aflibercept as well as other anti-VEGF treatments were a substantial improvement over previous treatments, and considered that this improvement applied to the class of drugs. In ...